# OnCo record avapritinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/avapritinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "avapritinib" ;
  schema:name "Avapritinib"@en ;
  schema:description "Avapritinib is the first drug for GIST driven by the PDGFRA D842V mutation, which resists every other kinase inhibitor; it is also approved for systemic mastocytosis."@en ;
  schema:url <https://onco.cc/drugs/avapritinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Avapritinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q29213676> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Avapritinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (PDGFRA D842V / KIT)" ;
  schema:alternateName "Ayvakit" ;
  onco:approval "US 2020: Unresectable/metastatic GIST with PDGFRA exon 18 mutation including D842V", "US 2021: Advanced systemic mastocytosis", "EU 2020: EU brand Ayvakyt" ;
  onco:related <https://onco.cc/biomarkers/pdgfra-exon-18-d842v/> ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/gist-pdgfra-d842v/>, <https://onco.cc/cancers/systemic-mastocytosis/>, <https://onco.cc/cancers/indolent-systemic-mastocytosis/>, <https://onco.cc/cancers/advanced-systemic-mastocytosis/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kit/> ;
  onco:companies <https://onco.cc/companies/sanofi/> ;
  onco:trials <https://onco.cc/trials/voyager/>, <https://onco.cc/trials/nct03731260/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-navigator-avapritinib-heinrich-lancet-oncol-2020/> .